3.5-Real-World-Use-T1D

Initiate KERENDIA as part of comprehensive care

Across CKD associated with T2D and HF LVEF ≥40% indications,
KERENDIA has:

5+ years

of real-world experience in CKD associated with T2D, with reach expanding since approval in HF LVEF ≥40% in 2025 and CKD associated with T1D in 2026¹

Over

65,000

prescribing HCPs²⁴*

More than

330,000

patients treated²⁴*

In adults with CKD associated with T2D,

KERENDIA is recommended in 3 leading endocrinology/nephrology guidelines, including
ADA, KDIGO, and AACE^9,23,25

Guidelines

Treatment strategy is based upon individual patient needs and physician discretion.^9,23,25

*IQVIA NPA data, July 2021 to March 2026. Treatments are normalized for 30-day scripts.²⁴

AACE=American Association of Clinical Endocrinology; ADA=American Diabetes Association; CKD=chronic kidney disease; HCP=healthcare professional; HF LVEF=heart failure with left ventricular ejection fraction; KDIGO=Kidney Disease: Improving Global Outcomes; NPA=National Prescription Audit; T1D=type 1 diabetes; T2D=type 2 diabetes.

IMPORTANT SAFETY INFORMATION AND INDICATIONS

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS:

Hypersensitivity to any component of this product
Concomitant use with strong CYP3A4 inhibitors
Patients with adrenal insufficiency

WARNINGS AND PRECAUTIONS:

Hyperkalemia: KERENDIA can cause hyperkalemia. The risk for developing hyperkalemia increases with decreasing kidney function and is greater in patients with higher baseline potassium levels or other risk factors for hyperkalemia.

Measure serum potassium and eGFR in all patients before initiation of treatment with KERENDIA and dose accordingly. Do not initiate KERENDIA if serum potassium is >5 mEq/L. Measure serum potassium periodically during treatment with KERENDIA and adjust dose accordingly. More frequent monitoring may be necessary for patients at risk for hyperkalemia, including those on concomitant medications that impair potassium excretion or increase serum potassium.
Worsening of Renal Function in Patients with Heart Failure: KERENDIA can cause worsening of renal function in patients with heart failure. Rarely, severe events associated with worsening renal function, including events requiring hospitalization, have been observed.

Measure eGFR in all patients before initiation of treatment or with dose titration of KERENDIA and dose accordingly. Initiation of KERENDIA in patients with heart failure and an eGFR <25 mL/min/1.73 m² is not recommended. Measure eGFR periodically during maintenance treatment with KERENDIA in patients with heart failure. Consider delaying up-titration or interrupting treatment with KERENDIA in patients who develop clinically significant worsening of renal function.

MOST COMMON ADVERSE REACTIONS:

The adverse reactions reported in ≥1% of patients on KERENDIA and more frequently than placebo were hyperkalemia (14% vs 6.9%), hypotension (4.6% vs 3%), and hyponatremia (1.3% vs 0.7%). Events related to worsening renal function were reported more frequently in the KERENDIA group (18%) compared with placebo (12%) in patients with HF LVEF ≥40%.

DRUG INTERACTIONS:

Strong CYP3A4 Inhibitors: Concomitant use of KERENDIA with strong CYP3A4 inhibitors is contraindicated. Avoid concomitant intake of grapefruit or grapefruit juice.
Moderate and Weak CYP3A4 Inhibitors: Monitor serum potassium during drug initiation or dosage adjustment of either KERENDIA or the moderate or weak CYP3A4 inhibitor, and adjust KERENDIA dosage as appropriate.
Strong and Moderate CYP3A4 Inducers: Avoid concomitant use of KERENDIA with strong or moderate CYP3A4 inducers.
Sensitive CYP2C8 Substrates at KERENDIA 40 mg: Monitor patients more frequently for adverse reactions caused by sensitive CYP2C8 substrates if KERENDIA 40 mg is coadministered with such substrates, since minimal concentration changes may lead to serious adverse reactions.

USE IN SPECIFIC POPULATIONS:

Lactation: Avoid breastfeeding during treatment with KERENDIA and for 1 day after treatment.
Hepatic Impairment: Avoid use of KERENDIA in patients with severe hepatic impairment (Child Pugh C) and consider additional serum potassium monitoring with moderate hepatic impairment (Child Pugh B).

INDICATIONS:

KERENDIA (finerenone) is indicated to:

reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with Type 2 diabetes (T2D) (10 mg, 20 mg tablets)
reduce urinary albumin-to-creatinine ratio (UACR), which is expected to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline and end-stage kidney disease in adults with CKD associated with Type 1 diabetes (T1D) (10 mg, 20 mg tablets)
reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adult patients with heart failure with left ventricular ejection fraction (HF LVEF) ≥40% (10 mg, 20 mg, 40 mg tablets)

Please see the full Prescribing Information for KERENDIA.

AACE=American Association of Clinical Endocrinology; ACE=angiotensin-converting enzyme; ACEi=angiotensin-converting enzyme inhibitor;
ACR=albumin-to-creatinine ratio; ADA=American Diabetes Association; ARB=angiotensin receptor blocker; CKD=chronic kidney disease;
CV=cardiovascular; CVD=cardiovascular disease; eGFR=estimated glomerular filtration rate; ESC=European Society of Cardiology; HF=heart failure;
KDIGO=Kidney Disease: Improving Global Outcomes; nsMRA=nonsteroidal mineralocorticoid receptor antagonist; RAS=renin-angiotensin system;
RASi=renin-angiotensin system inhibitor; T2D=type 2 diabetes; T2DM=type 2 diabetes mellitus; UACR=urine albumin-to-creatinine ratio.

REFERENCES

Initiate KERENDIA as part of comprehensive care

5+ years

65,000

330,000

2022 Grade 1A recommendation

2022 ADA and KDIGO Consensus Statement

2024 Grade 2A recommendation

2026 Grade A recommendations